Rotated component matrix | ||||
---|---|---|---|---|
Question: Which of the following statements would you tend to agree with? (N = 3,829) | Overall approval | Comp. 1 (variance clarif.: 18.0%) | Comp. 2 (variance clarif.: 17.8%) | Comp. 3 (variance clarif.: 13.4%) |
DHAs reinforce patient motivation to improve their health | 66% | .659 | .752 | .034 |
DHAs reinforce patient compliance | 55% | .443 | .796 | -.101 |
I do not think that DHAs provide adequate data privacy | 45% | -.182 | .002 | -.769 |
DHAs give patients the sense of having more control over their health and keeping healthy (empowerment) | 39% | .492 | .198 | -.096 |
DHAs are too complicated for many patients, which leads to health data errors being collected or treatment failure in extreme cases | 37% | -.662 | .513 | -.162 |
DHAs help increase patient awareness for health and disease issues | 28% | .431 | .675 | .366 |
DHAs help schedule doctors’ appointments more effectively | 26% | .500 | .262 | -.058 |
DHAs make the doctor-patient relationship less personal | 22% | -.220 | -.448 | -.103 |
DHAs facilitate rapid disease and disease risk recognition and diagnosis | 22% | .828 | .300 | .146 |
DHAs take the burden off doctors and nursing staff as they no longer need to deal with collecting health data and measurements | 20% | .116 | .525 | .296 |
DHAs cause more rather than less work for doctors, as they give doctors more responsibilities to tend to | 19% | -.326 | .205 | .631 |
DHAs make it possible to reach new patient groups | 19% | -.002 | -.033 | .025 |
DHAs cause floods of data not relevant or beneficial to effective treatment | 18% | -.276 | .186 | -.705 |
DHAs are too time-consuming for patients and doctors to use | 17% | -.197 | -.469 | -.101 |
DHAs facilitate doctor-patient communication | 11% | .324 | .723 | .017 |
The additional information that DHAs collect make it possible to treat patients in a more individual and effective way | 6% | .263 | .527 | .235 |
DHAs lead to patients taking their diagnosis and treatment into their own hands | 4% | -.122 | -.162 | -.401 |